Dry Eye Disease and Essential Fatty Acids
Abstract
Abstract Dry eye disease (DED) is common, multifactorial disease in which vicious cycle of inflammation on ocular surface plays a major role. Thus, therapeutic approaches focused on the modulation of ocular surface inflammation have been introduced, and topical and systemic anti-inflammatory drugs including corticosteroids, cyclosporine A, and doxycycline have been shown to be effective in treatment of DED. Recent studies suggest that supplementation of omega-3 (ω3) and omega-6 (ω6) essential fatty acids may be helpful for modulation of ocular surface inflammation, and systemic and topical application of the essential fatty acids can be an alternative strategy for the treatment of DED. In this chapter, the results of the experimental studies and clinical trial to evaluate the efficacy of systemic and topical ω3 and ω6 essential fatty acids supplementation for the treatment of DED will be summarized. Therapeutic guideline, possible side effects, and future perspective of the supplementation of the essential fatty acid will also be discussed.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.